IGF-1 LR3 Research Peptide — Extended Half-Life Variant, COA Verified
IGF-1 LR3 (Insulin-like Growth Factor 1 Long Arg3) is a modified analogue of endogenous IGF-1, engineered with an arginine substitution at position 3 and an N-terminal extension of 13 amino acids. These structural modifications significantly reduce binding affinity to IGF binding proteins (IGFBPs), resulting in a substantially extended half-life compared to native IGF-1.
Mechanism of Action
Native IGF-1 is rapidly bound and inactivated by IGF binding proteins in circulation. The LR3 modification at position 3 — replacing glutamic acid with arginine — prevents IGFBP binding, keeping the peptide biologically active for longer periods. IGF-1 LR3 binds to the IGF-1 receptor, which activates downstream PI3K/Akt and MAPK/ERK signaling pathways involved in cell growth, differentiation, and protein synthesis.
Research Overview
IGF-1 LR3 is widely used in cell culture and in vivo research models due to its prolonged activity. It has been studied in the context of muscle cell proliferation and differentiation, metabolic regulation, and growth factor signaling research. Its extended half-life makes it particularly useful in research protocols requiring sustained receptor activation.
Product Details
Format: Lyophilized powder | Purity: >99% | Testing: Third-party HPLC and MS verified | Packaging: Sterile sealed vial | Available in: 1mg vials | Pricing from $29.99 per vial
Storage Instructions
Store lyophilized powder in a cool, dry place. Refrigerate after reconstitution at 2–8°C. Protect from light and avoid freeze-thaw cycles.
IGF-1 LR3 is intended for research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.
